Rituximab use in the treatment of children with nephrotic syndrome

Authors

  • L.I. Vakulenko Dnipro State Medical University, Dnipro, Ukraine https://orcid.org/0000-0003-3823-6134
  • O.M. Lytvynova Communal Enterprise “Dnipropetrovsk Regional Children’s Clinical Hospital of Dnipropetrovsk Regional Council”, Dnipro, Ukraine
  • I.V. Posmitjuha Communal Enterprise “Dnipropetrovsk Regional Children’s Clinical Hospital of Dnipropetrovsk Regional Council”, Dnipro, Ukraine

DOI:

https://doi.org/10.22141/2307-1257.11.2.2022.365

Keywords:

children, steroid-sensitive nephrotic syndrome, ritu­ximab

Abstract

Background. High recurrence rates of nephrotic syndrome in children and consequences in the form of steroid dependence and a high risk of side effects from corticosteroids as a result involve immunosuppressive steroid-preserving agents that would increase long-term remission. Rituximab, a chimeric anti-CD20 monoclonal antibody that inhibits CD20-mediated B-cell proliferation and differentiation, has been identified as a possible alternative treatment. The purpose of the study — to estimate the efficacy and safety of treatment recurrence of nephrotic syndrome in children using rituximab like we did it on three clinical cases. Materials and methods. The experience of rituximab in children was analyzed according to the databases of Scopus, Web of Science, MedLine, The Cochrane Library, EMBASE, Global Health and our own study of the treatment of three children with steroid-sensitive nephrotic syndrome was presented. Results. Treatment of nephrotic syndrome in three children who are 5 to 7 years with rituximab was conducted. One child had a second recurrence, two children had a first recurrence. The previous episode of nephrotic syndrome in all children was treated according to the recommendations of KDIGO 2021. All patients received rituximab (two intravenous injections two weeks apart) at a dose of 15 mg/kg for 5–6 hours with prior administration of methylprednisolone at a dose of 7–10 mg/kg. One child had side effects to the first administration of rituximab in the form of hypotension 70/40 and tachycardia 116–118. Reducing the speed of administration helped to eliminate side effects. The next injection in two weeks the child endured well. The other two children had no side effects to both rituximab injections. Moreover after 1 month of rituximab administration was without side effects or hematological changes. The next administration of ritu­ximab is scheduled in 6 months after the last administration with prior control of CD20 level. Conclusions. In general a review of studies of rituximab confirms the high efficacy of the medication in nephrotic syndrome in children and the requirement for long-term evaluation. Rituximab can be considered as a first-line treatment for recurrence of nephrotic syndrome, including in resource-limited settings. Our own experience with rituximab in recurrent nephrotic syndrome has revealed slight short-term side effects.

Downloads

Download data is not yet available.

References

McKay AM, Parekh RS, Noone D. Therapeutic trials in difficult to treat steroid sensitive nephrotic syndrome: challenges and future directions. Pediatr Nephrol. 2022 Apr 28:1-18. doi: 10.1007/s00467-022-05520-6.

Colucci M, Carsetti R, Cascioli S, et al. B Cell Reconstitution after Rituximab Treatment in Idiopathic Nephrotic Syndrome. J Am Soc Nephrol. 2016 Jun;27(6):1811-22. doi: 10.1681/ASN.2015050523.

Guzmán Morais B, Ordóñez Álvarez FÁ, Santos Rodríguez F, Martín Ramos S, Fernández Novo G. Rituximab treatment in pediatric patients with steroid-dependent nephrotic syndrome: A tertiary hospital. An Pediatr (Engl Ed). 2022 Feb;96(2):83-90. doi: 10.1016/j.anpede.2020.12.019.

Kallash M, Smoyer WE, Mahan JD. Rituximab Use in the Management of Childhood Nephrotic Syndrome. Front Pediatr. 2019 May 10;7:178. doi: 10.3389/fped.2019.00178.

Larkins NG, Liu ID, Willis NS, Craig JC, Hodson EM. Non-corticosteroid immunosuppressive medications for steroid-sensitive nephrotic syndrome in children. Cochrane Database Syst Rev. 2020 Apr 16;4(4):CD002290. doi: 10.1002/14651858.CD002290.pub5.

Nagano C, Sako M, Kamei K, et al. Study protocol: multicenter double-blind, randomized, placebo-controlled trial of rituximab for the treatment of childhood-onset early-stage uncomplicated frequently relapsing or steroid-dependent nephrotic syndrome (JSKDC10 trial). BMC Nephrol. 2019 Aug 2;20(1):293. doi: 10.1186/s12882-019-1470-3.

Vivarelli M. Deschênes G. Idiopathic Nephrotic syndrome Working Group Report. Sep 2016. Available from: https://www.espn-online.org/wp-content/uploads/b_upload/IdiopathicNephroticsyndromeWorkingGroupReport2016.pdf.

Ravani P, Rossi R, Bonanni A, et al. Rituximab in Children with Steroid-Dependent Nephrotic Syndrome: A Multicenter, Open-Label, Noninferiority, Randomized Controlled Trial. J Am Soc Nephrol. 2015 Sep;26(9):2259-66. doi: 10.1681/ASN.2014080799.

Topaloğlu R, Gülhan B, Çelegen K, et al. Rituximab for Children With Difficult-to-Treat Nephrotic Syndrome: Its Effects on Disease Progression and Growth. Front Pediatr. 2019 Jul 30;7:313. doi: 10.3389/fped.2019.00313.

Veltkamp F, Rensma LR, Bouts AHM; LEARNS consortium. Incidence and Relapse of Idiopathic Nephrotic Syndrome: Meta-analysis. Pediatrics. 2021 Jul;148(1):e2020029249. doi: 10.1542/peds.2020-029249.

Liu S, Gui C, Lu Z, Li H, Fu Z, Deng Y. The Efficacy and Safety of Rituximab for Childhood Steroid-Dependent Nephrotic Syndrome: A Systematic Review and Meta-Analysis. Front Pediatr. 2021 Aug 20;9:728010. doi: 10.3389/fped.2021.728010.

Basu B, Sander A, Roy B, Preussler S, Barua S, Mahapatra TKS, Schaefer F. Efficacy of Rituximab vs Tacrolimus in Pediatric Corticosteroid-Dependent Nephrotic Syndrome: A Randomized Clinical Trial. JAMA Pediatr. 2018 Aug 1;172(8):757-764. doi: 10.1001/jamapediatrics.2018.1323.

Iijima K, Sako M, Nozu K, et al; Rituximab for Childhood-onset Refractory Nephrotic Syndrome (RCRNS) Study Group. Rituximab for childhood-onset, complicated, frequently relapsing nephrotic syndrome or steroid-dependent nephrotic syndrome: a multicentre, double-blind, randomised, placebo-controlled trial. Lancet. 2014 Oct 4;384(9950):1273-81. doi: 10.1016/S0140-6736(14)60541-9.

Bazargani B, Noparast Z, Khedmat L, et al. Efficacy of rituximab therapy in children with nephrotic syndrome: a 10-year experience from an Iranian pediatric hospital. BMC Pediatr. 2022 Jan 12;22(1):36. doi: 10.1186/s12887-022-03109-4.

Ivanov DD, Dyadyk OO, Rotova SO, Ivanovа MD. 10-year personal experience of rituximab use in nephrological patients. Počki. 2020;9(2):99-104. doi: 10.22141/2307-1257.9.2.2020.203409. (in Ukrainian).

Boumediene A, Vachin P, Sendeyo K, et al. NEPHRUTIX: A randomized, double-blind, placebo vs Rituximab-controlled trial assessing T-cell subset changes in Minimal Change Nephrotic Syndrome. J Autoimmun. 2018 Mar;88:91-102. doi: 10.1016/j.jaut.2017.10.006.

Ahn YH, Kim SH, Han KH, et al. Efficacy and safety of rituximab in childhood-onset, difficult-to-treat nephrotic syndrome: A multicenter open-label trial in Korea. Medicine (Baltimore). 2018 Nov;97(46):e13157. doi: 10.1097/MD.0000000000013157.

Meeuwisse C, Morgan CJ, Samuel S, Alexander RT, Rodriguez-Lopez S. Rituximab Use for the Treatment of Childhood Nephrotic Syndrome by Canadian Pediatric Nephrologists: A National Survey. Can J Kidney Health Dis. 2022 Mar 11;9:20543581221079959. doi: 10.1177/20543581221079959.

Kidney Disease: Improving Global Outcomes (KDIGO) Glomerular Diseases Work Group. KDIGO 2021 Clinical Practice Guideline for the Management of Glomerular Diseases. Kidney Int. 2021 Oct;100(4S):S1-S276. doi: 10.1016/j.kint.2021.05.021.

Trautmann A, Vivarelli M, Samuel S, et al; International Pediatric Nephrology Association. IPNA clinical practice recommendations for the diagnosis and management of children with steroid-resistant nephrotic syndrome. Pediatr Nephrol. 2020 Aug;35(8):1529-1561. doi: 10.1007/s00467-020-04519-1.

Sinha A, Bhatia D, Gulati A, et al. Efficacy and safety of rituximab in children with difficult-to-treat nephrotic syndrome. Nephrol Dial Transplant. 2015 Jan;30(1):96-106. doi: 10.1093/ndt/gfu267.

Published

2022-07-13

How to Cite

Vakulenko, L., Lytvynova, O., & Posmitjuha, I. (2022). Rituximab use in the treatment of children with nephrotic syndrome. KIDNEYS, 11(2), 86–91. https://doi.org/10.22141/2307-1257.11.2.2022.365

Issue

Section

Cover story